Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients

Annals of Oncology

Volumn 13, Issue 5, 2002, Pages 760-769

  Cellarier, E ^a,b   Terret, C ^c   Labarre, P ^b   Ouabdesselam, R ^a   Cure H ^a   Marchenay, C ^a,b   Maurizis, J C ^b   Madelmont, J C ^b   Chollet, P ^a,b   Armand, J P ^c  

^a Center Jean Perrin   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chloroethylnitrosourea; Cystemustine; Hematotoxicity; Pharmacokinetic pharmacodynamic relationships; Phase I

Indexed keywords

CYSTEMUSTINE; N' (2 CHLOROETHYL) N (2 (METHYLSULFONYL)ETHYL) N' NITROSOUREA; N'-(2-CHLOROETHYL)-N-(2-(METHYLSULFONYL)ETHYL)-N'-NITROSOUREA; NITROSOUREA DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GRANULOCYTE; HUMAN; LEUKOCYTE; LINEAR SYSTEM; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA; ADOLESCENT; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM; PROBABILITY; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN; LINEAR MODELS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; NITROSOUREA COMPOUNDS; PROBABILITY; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035985307     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf098     Document Type: Article

References (40)

1. An overview of the status of the nitrosoureas in other tumors
2. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems
3. Decomposition of N-(2-chloroethyl)-N-nitrosoureas in aqueous media
4. New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results
5. Cytostatic action of two nitrosoureas derived from cysteamine
6. Antitumor activity of the novel nitrosourea S10036 in rodent tumors
7. Nitrosoureas: A review of experimental antitumor activity
8. Disposition of new sulphur-containing 2-(chloroethyl) nitrosoureas in rats
9. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: An intrapatient escalation scheme
10. Phase II study of cystemustine in advanced head and neck cancer. A trial of the EORTC Clinical Screening Group
11. Phase II study of cystemustine in advanced renal cancer
12. Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group
13. 2 in advanced soft tissue sarcoma: A trial of the EORTC Early Clinical Studies Group
14. Results of phase II trial with cystemustine at 90 mg/sq.m as a first- or second-line treatment in advanced malignant melanoma: A trial of the EORTC Clinical Studies Group
15. 2) in advanced or metastatic pretreated lung carcinoma
16. Phase II trial of cystemustine, a new nitrosourea, as treatment of high grade brain tumors in adults
17. Qualitative and quantitative analysis of a new sulphur-containing nitrosourea in blood by high-performance liquid chromatography
18. Pharmacokinetics of two new 2-chloroethylnitrosoureas in cancer patients submitted to phase II clinical trials
19. The pulmonary toxicity of nitrosoureas
20. 6-alkylguanine-DNA-alkyltransferase
21. Nephrotoxicity of nitrosoureas
22. Nephrotoxicity of semustine
23. Hepatic toxicity of nitrosourea analogues
24. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer
25. Comparative pharmacokinetics of 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea in rats and patients and extrapolation to clinical trials
26. Pharmacokinetics of tauromustine in cancer patients. Phase I studies
27. Hepatic intra-arterial infusion of fotemustine: Pharmacokinetics
28. Study of the clinical pharmacokinetics of fotemustine in various tumor indications
29. The nitrosoureas: Carmustine (BCNU) and lomustine (CCNU)
30. Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S10036): Mice, rats, monkeys, dogs and man
31. Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases
32. Chloroethylnitrosourea cancer chemotherapeutic agents
33. Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(β-maltosyl)-1-nitrosourea (TA-077). III. Pharmacokinetics of a new nitrosourea antitumor agent TA-077 in humans (a phase I study)
34. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea
35. 6-alkylguanine by alkyltransferases
36. 6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity
37. 6-benzyl-2′-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea
38. 2-acetylguanosine of therapeutic index on nude mice bearing resistant human melanoma
39. 6-methylguanine-DNA methyltransferase by methionine in human tumour cells
40. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts